Edit Buckingham Institute for Transitional Medicine

Buckingham Institute for Translational Medicine


BITM is an internationally recognised research group with a track record in drug discovery, including beta3-adrenoceptor agonists for obesity, orexin and MCH-antagonists, and the insulin sensitiser drug rosiglitazone.

Our focus is encompassed by 3 research themes, which highlight our combined basic research, drug discovery and clinical expertise. The aim of our pre-clinical research is to inform drug development and enhance underlying biological understanding. As part of the University of Buckingham Medical School and our long-standing academic, clinical and pharmaceutical collaborations we are translating our key research themes into clinical studies and ultimately therapeutics.


Professor Mike Cawthorne

500 Internal Server Error

Internal Server Error

The server encountered an internal error and was unable to complete your request. Either the server is overloaded or there is an error in the application.